Advances in Hormone Receptor Positive Metastatic Breast Cancer

home / insights / advances-in-hormone-receptor-positive-metastatic-breast-cancer

Recommendations for managing HR-positive, HER2-negative metastatic breast cancer with CDK4/6 inhibitors and endocrine therapy.

breast oncologist

EP. 1: Treatment Advances in HR+ Advanced Breast Cancer

Aditya Bardia, MD, MPH, Massachusetts General Hospital
October 27th 2021
breast cancer

EP. 2: First-Line Approaches for HR+ Metastatic Breast Cancer

Gabriel N. Hortobagyi, MD;Sara A. Hurvitz, MD
November 10th 2021
breast oncologist

EP. 3: Updates to MONALEESA-2 Data in HR+ MBC

Gabriel N. Hortobagyi, MD
November 10th 2021
breast oncologist

EP. 4: HR+ MBC: Ribociclib and Patient Quality of Life

Aditya Bardia, MD
November 17th 2021
breast cancer doctor

EP. 5: HR+ MBC: Abemaciclib Plus Endocrine Therapy

Sara A. Hurvitz, MD
November 22nd 2021
Sara Hurvitz, MD

EP. 6: HR+ MBC: Palbociclib Plus Endocrine Therapy on Time to Chemotherapy

Sara A. Hurvitz, MD
November 22nd 2021
breast cancer

EP. 7: HR+ MBC: Genomic Testing and Treatment Guidance

Aditya Bardia, MD
November 29th 2021
breast oncologist

EP. 8: PI3K Inhibitors for HR+ MBC

Gabriel Hortobagyi, MD, MACP, FASCO;Sara A. Hurvitz, MD
November 29th 2021
breast oncologist

EP. 9: Novel Therapies Under Investigation for HR+ MBC

Gabriel Hortobagyi, MD, MACP, FASCO;Aditya Bardia, MD;Sara A. Hurvitz, MD
December 6th 2021
breast oncologist

EP. 10: Advances Treating HR+ Metastatic Breast Cancer

Gabriel Hortobagyi, MD, MACP, FASCO;Sara A. Hurvitz, MD;Aditya Bardia, MD
December 6th 2021